Abstract
Interhospital transport of critically unwell children exacerbates physiological stress, increasing the risk of deterioration during transport. Due to the nature of illness and interventions occurring in this cohort, defining “normal” vital sign ranges is impossible, which can make identifying deterioration events difficult. A novel data-driven approach was developed to identify adverse respiratory and cardiovascular events in critically ill children during interhospital transport. In this retrospective cohort study of 1,519 transports (July 2016 to May 2021), vital signs were recorded at one-second intervals and then analysed using an adaptation of Bollinger Bands, a technique borrowed from financial market analysis. This method dynamically established each patient’s stable ranges for heart rate, blood pressure, oxygen saturation, and other respiratory parameters, and flagged adverse events when multiple parameters simultaneously fell outside their expected ranges. Adverse respiratory events were identified when oxygen saturation deviated below a dynamically defined threshold alongside at least one additional respiratory parameter. Cardiovascular events were defined by concurrent deviations in blood pressure and heart rate. Overall, 15.6 percent of transports had one or more adverse respiratory events, and 21.5 percent had at least one adverse cardiovascular event. To validate these labels, the number of adverse events and the cumulative duration of vital sign instability during transport were compared against clinical markers of deterioration. Each additional respiratory event was associated with increased odds of receiving respiratory support during transport and higher 30-day mortality, while each additional cardiovascular event was associated with increased odds of receiving vasoactive support during transport. Our method detects clinically meaningful respiratory and cardiovascular adverse events during transport. The approach is readily adaptable to other high-resolution intensive care datasets, for both retrospective labelling as well as automated, real-time identification of adverse events in the clinical setting, offering a foundation for improved monitoring and early intervention in critically ill patients.
Competing Interest Statement
GD reports speaker honoraria from Vertex Pharmaceuticals and Chiesi Ltd, and advisory board and clinical trial leadership roles with Vertex, unrelated to the current manuscript. PR reports travel support for conference attendance from Fisher and Paykel Healthcare Limited.
Funding Statement
Yes
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by Great Ormond Street Hospital's (GOSH) Research and Innovation Department, under ethical approvals for use of routine de-identified healthcare and operational hospital data (Research Database, NHS REC reference 21/LO/0646).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data supporting this study are subject to ethical restrictions. Use of the underlying sensitive patient information requires appropriate ethical approval. Researchers seeking access must obtain permission from the Children’s Acute Transport Service and Great Ormond Street Hospital.